Premier Health Group Inc. (PHGI:CSE; PHGRF:OTCQB; 6PH:FSE) announced in a news release it launched a strategy to expand its footprint in the medical cannabis industry internationally.
Its approach is to educate physicians about medical marijuana through the adjunct software embedded in its electronic medical records (EMR) platform. It is working to sell its EMR product in the quickly growing medical cannabis markets around the world, including the United States, the United Kingdom and Australia.
Today, according to the company release, medical cannabis is legal in about 30 countries in some capacity. A handful of others also allow its use on a strictly limited basis, as in cannabis-derived pharmaceuticals only.
The announcement notes the global medical cannabis industry is expected to generate about $40.9 billion by the end of 2024, according to Zion Market Research. The EMR market is expected to grow to $30.4 billion by 2023, P&S Market Research showed.
Premier stated a gap exists, particularly in countries lagging behind Canada in their adoption of medical cannabis, between patients' needs and/or desires and primary care physicians' comfort level with medical cannabis, as well as their being knowledgeable enough to prescribe it.
Premier Health aims to bridge that divide by educating physicians with the data and tools available through its EMR software, which will help them prescribe the most appropriate cannabis product at the ideal dosage. "By innovating and integrating these increasingly in demand capabilities, Premier Health will be equipped to significantly increase its market share of the $30 billion EMR market," CEO Dr. Essam Hamza said in the release.[NLINSERT]
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees. As of the date of this article, an affiliate of Streetwise Reports has a consulting relationship with Premier Health Group Inc. Please click here for more information. Within the last six months, an affiliate of Streetwise Reports has disseminated information about the private placement of the following companies mentioned in this article: Premium Health Group Inc.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Premier Health Group Inc., a company mentioned in this article.